Targeting of peripheral blood T lymphocytes

Springer Seminars in Immunopathology

Volumn 18, Issue 2, 1996, Pages 211-226

  Bolhuis, Reinder L H ^a,c   Hoogenboom, Hennie R ^b   Gratama, Jan Willem ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN RECEPTOR; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR;

CELL INTERACTION; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HUMAN; IMMUNOGENETICS; IMMUNOTHERAPY; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TARGET CELL;

ANIMALS; EPITOPES; HUMANS; IMMUNOLOGIC MEMORY; LEUKOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0029787912     PISSN: 03444325     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00820667     Document Type: Review

References (123)

1. Bakács T, Lee J, Belen Moreno M, Zacharchuk CM, Cole MS, Yun Tso J, Paik CH, Ward JM, Segal DM (1995) A bispecific antibody prolongs survival in mice bearing lung metastases of syngeneic mammary adenocarcinoma. Int Immunol 6:947
2. Becker MLB, Near R, Mudgett-Hunter M, Margolies MN, Kubo RT, Kaye J, Hedrick SM (1989) Expression of hybrid immunoglobulin - T cell receptor protein in transgenic mice. Cell 58:911
3. Belen Moreno M, Titus JA, Cole MS, Yun Tso J, Nhat Le, Paik CH, Bakács T, Zacharchuk CM, Segal DM, Wunderlich JR (1995) Bispecific antibodies retarget murine T cell cytotoxicity against syngeneic breast cancer in vitro and in vivo. Cancer Immunol Immunother 40:182
4. Berke G (1995) The CTLs kiss of death. Cell 81:9
5. Beun GD, Eendenburg DH van, Corver WE, Van de Velde CJH, Fleuren GJ (1992) T-cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model. I. Significant bispecific lysis of syngeneic colon carcinoma CC531 is critically dependent on prolonged preactivation of effector T-lymphocytes by immobilized anti-T-cell receptor antibody. J Immunother 11:238
6. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan GS, Whitlow M (1988) Single chain antigen binding proteins. Science 242:423
7. Blank-Voorthuis CJAC, Braakman E, Ronteltap CPM, Tilly BC, Sturm E, Warnaar SO, Bolhuis RLH (1993) Clustered CD3/TCR complexes do not transduce activation signals after bispecific monoclonal antibody-triggered lysis by CTL via CD3. J Immunol 151:2904
8. Blue ML, Hafler DA, Craig KA, Levine H, Schlossman SF (1987) Phosphorylation of CD4 and CD8 molecules following T cell triggering. J Immunol 139:3949
9. + cytotoxic T lymphocytes via CD2 50KD sheep erythrocyte receptor. J Immunol 136:3939
10. Bolhuis RLH, Gravekamp C, Van de Griend RJ (1986) Cell-cell interactions. Clin Immunol Allergy 6:29
11. Bolhuis RLH, Sturm E, Braakman E (1991) T-cell targeting in cancer therapy. Cancer Immunol Immunother 34:1
12. Bolhuis RLH, Lamers CHJ, Goey SH, Eggermont AMM, Trimbos JBMZ, Stoter G, Lanzavecchia A, Di Re E, Miotti S, Raspagliesi F, Rivoltini L, Colnaghi MI (1992) Adoptive immunotherapy of ovarian carcinoma with bs-mAb-targeted lymphocytes: a multicenter study. Int J Cancer 7:78
13. Borst J, Van de Griend RJ, Van Oostveen JW, Ang S-L, Melief CJ, Seidman JG, Bolhuis RLH (1987) A T-cell receptor γ/CD3 complex found on cloned functional lymphocytes. Nature 325:683
14. Braakman E, Goedegebuure PS, Vreugdenhil RJ, Segal DM, Shaw S, Bolhuis RLH (1990) ICAM-melanoma cells are relatively resistant to CDS-mediated T-cell lysis. Int J Cancer 46:475
15. 1 lymphoma with bispecific antibodies. J Immunol 147:4019
16. Brissinck J, Demanet C, Moser M, Leo O, Thielemans K (1993) Bispecific antibodies in lymphoma. Int Rev Immunol 10:187
17. Brocker T, Peter A, Traunecker A, Karjalainen K (1993) New simplified molecular design for functional T cell receptor. Eur J Immunol 23:1435
18. Burnett FM (1970) The concept of immunological surveillance. Prog Exp Tumor Res 13:1
19. Campbell IG, Jones TA, Foulkes WD, Trowsdale J (1991) Folate-binding protein is a marker for ovarian cancer. Cancer Res 51:5329
20. Canevari S, Stoter G, Arienti F, Bolis G, Colnaghi MI, Di Re EM, Eggermont AMM, Hoo Goey S, Gratama JW, Lamers CHJ, Nooy MA, Parmiani G, Raspagliesi F, Ravagnani F, Scarfone G, Trimbos JB, Warnaar SO, Bolhuis RLH (1995) Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 87:1463
21. Chothia C, Boswell BW, Lesk AM (1988) The outline structure of T-cell αβ receptor. EMBO J 7:3745
22. Colcher D, Bird R, Roselli M, Hardman KD, Johnson S, Pope S, Dodd SW, Pantoliano MW, Milenic DE, Schlom J (1990) In vivo tumor targeting of a recombinant single chain antigen-binding protein. J Natl Cancer Inst 82:1191
23. Coulie PG, Uyttenhove C, Wauters P, Manolios N, Klausner RD, Samelson LE, Van Snick J (1991) Identification of a murine monoclonal antibody specific for an allotypic determinant on mouse CD3. Eur J Immunol 21:1703
24. Culty M, Miyake K, Kincade PW, Sikorski E, Butcher EC, Underbill C (1990) The hyaluronate receptor is a member of the CD44 (H-CAM) family of cell surface glycoproteins. J Cell Biol 111:2765
25. Davis MM, Bjorkman PJ (1988) T-cell antigen receptor genes and T-cell recognition. Nature 334:395
26. Demanet C, Brissinck J, Van Mechelen M, Leo O, Thielemans K (1991) Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype × anti-CD3). J Immunol 147:1091
27. Demanet C, Brissinck J, Moser M, Leo O, Thielemans K (1992) Bispecific antibody therapy of two murine B-cell lymphomas. Int J Cancer 7:67
28. 1 lymphoma. Cancer Res 54:2973
29. Dennert G, Podack ER (1983) Cytolysis by H-2-specific T killer cells. Assembly of tubular complexes on target membranes. J Exp Med 157:1483
30. Ehrlich P (1909) Über den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd 35: 273
31. Eshhar Z, Waks T, Gross G, Schindler DG (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 90:720
32. Eshhar Z, Gross G, Treisman J (1993) Modifying the specificity of T cells using chimeric Ig/TCR genes. In: Gallagher G, Rees RC, Reinolds CW (eds) Practical approach to tumor immunology. IRL Press, Oxford, pp 346-368
33. Eshhar Z, Gross G, Waks T, Lustgarten J, Bach N, Ratner A, Treisman J, Schindler DG (1995) T-bodies: chimeric T-cell receptors with antibody-type specificity. Methods: A companion to Method Enzymol 8:133
34. Galandrini R, Albi N, Tripodi G, Zarcone D, Terenzi A, Moretta A, Grossi CE, Velardi A (1993) Antibodies to CD44 trigger effector functions of human T cell clones. J Immunol 150:4225
35. Garrido MA, Valdayo MJ, Winkler DF, Titus JA, Hecht TT, Perez P, Segal DM, Wunderlich JR (1990) Targeting human T lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells in nu/nu mice. Cancer Res 50:4227
36. Geiger B, Rosen D, Berke G (1982) Spatial relationships of microtubule-organizing centers and the contact area of cytotoxic T lymphocytes and target cells. J Cell Biol 95:137
37. + T lymphocytes via CD2 requires triggering via the T11.1 epitope only. J Immunol 142:1797
38. Goedegebuure SP, Braakman E, Segal DM, Vreugdenhil RJ, Bolhuis RLH (1990) Lymphocyte leukocyte function-associated antigen 1 interacting with target cell intercellular adhesion molecule 1 coactivates cytolysis triggered via CD16 or the receptor involved in major histocompatibility antigen-unrestricted lysis. Int Immunol 2:1213
39. Goverman J, Gomez SM, Segesman KD, Hunkapiller T, Lang WE, Hood L (1990) Chimeric immunoglobulin-T-cell receptor complex formation and activation. Cell 60:929
40. Griffiths AD, Williams SC, Hartley O, Tomlinson OM, Waterhouse P, Crosby WL, Kontermann R, Jones PT, Low NM, Allison TJ, Prospero TD, Hoogenboom HR, Nissim A, Cox JPL, Harrison JL, Zaccolo M, Gherardi E, Winter G (1994) Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J 13:3245
41. Gross G, Gorochov G, Waks T, Eshhar Z (1989) Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity. Transplant Proc 21:127
42. Gross G, Waks T, Eshhar Z (1989) Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 86:10024
43. Gross G, Eshhar Z (1992) Endowing T cells with antibody specificity using chimeric T cell receptors. FASEB J 6:3370
44. Hawkins RE, Llewelyn MB, Russel SJ (1992) Monoclonal antibodies in medicine: adapting antibodies for clinical use. BMJ 305:1348
45. Henkart PA (1994) Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity 1:343
46. Holliger P, Prospero T, Winter G (1993) "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 90:6444
47. Holliger P, Winter G (1993) Engineering bispecific antibodies. Curr Opin Biotechnol 4:446
48. Hoogenboom HR, Griffiths AD, Johnson KS, Chiswell DJ, Hudson P, Winter G (1991) Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res 19:4133
49. Hoogenboom HR, Winter G (1992) Bypassing immunisation: human antibodies from synthetic repertoires of germ line VH-gene segments rearranged in vitro. J Mol Biol 20:381
50. Hwu P, Shafer GE, Treisman J, Schindler DG, Gross G, Cowherd R, Rosenberg SA, Eshhar Z (1993) Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor γ chain. J Exp Med 178:361
51. Ishiura S, Matsuda K, Koizumi H, Tsukahara T, Arahata K, Sugita H (1990) Calcium is essential for both the membrane binding and the lytic activity of pore-forming protein (perforin) from cytotoxic T lymphocytes. Mol Immunol 27:803
52. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S (1991) The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233
53. Jain RK (1989) Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst 81:570
54. Janssen RAJ, Kroesen BJ, Buter J, Mesander G, Sleijfer DT, The TH, Mulder NH, Ley L de (1995) Immunomodulatory effects of intravenous BIS-1 F(ab')2 administration in renal cell cancer patients. Br J Cancer 72:795
55. Jenkins MK (1994) The ups and downs of T cell costimulation. Immunity 1:443
56. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, Hengartner H, Golstein P (1994) Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265:528
57. Kojima H, Shinohara N, Suda T, Hanaoka S, Someya-Shirota Y, Takaga Y, Ohno H, Saito T, Katayama T, Yagita H, Okumura K, Shinkai Y, Alt FW, Matsuzawa A, Yonehara S, Nagata S, Takayama H (1994) Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes. Immunity 1:357
58. Kostelny SA, Cole MS, Tso (1992) Formation of a bispecific antibody by the use of leucine zippers. J Immunol 148:1547
59. Kroesen BJ, Haar A ter, Spakman H, Willemse P, Seijfer DT, Vries EGE de, Mulder NH, Berendsen HH, Limburg PC, The TH, Leij L de (1993) Local antitumor treatment in carcinoma patients with bispecific-monoclonal-antibody-redirecled T cells. Cancer Immunol Immunother 37:400
60. Kroesen BJ, Buter J, Sleijfer DT, Janssen RAJ, Graaf WTA van der, The TH, Leij L de. Mulder NH (1994) Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. Br J Cancer 70:652
61. Kupfer A, Dennert G, Singer SJ (1985) The reorientation of the Golgi apparatus and the microtubule-organizing center in the cytotoxic effector cell is a prerequisite in the lysis of bound target cells. J Mol Cell Immunol 2:37
62. Kupfer A, Singer SJ, Janeway CA, Swain SL (1987) Coclustering of CD4 (L3T4) molecule with the T-cell receptor is induced by specific direct interaction of helper T cells and antigen-presenting cells. Proc Natl Acad Sci USA 84:5888
63. Kuwana Y, Asakura Y, Utsuomiya N, Nakanishi M, Arata Y, Itoh S, Nagase F, Kurosawa Y (1987) Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun 149:960
64. Lamers CHJ, Gratama JW, Warnaar SO, Stoter G, Bolhuis RLH (1995) Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated lymphocytes. Int J Cancer 60:450
65. Lanzavecchia A, Scheidegger D (1987) The use of hybrid hybridoma to target human cytotoxic T lymphocytes. Eur J Immunol 17:105
66. Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA (1987) Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci USA 84:1374
67. Lesley J, Hyman R, Kincade PW (1993) CD44 and its interaction with extracellular matrix. Adv Immunol 54:271
68. Lichtenheld MG, Olsen KJ, Lu P, Lowrey DM, Hameed A, Hengartner H, Podack ER (1988) Structure and function of human perforin. Nature 335:448
69. Linsley PS, Ledbetter JA (1993) The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 11:191
70. Lowin B, Hahne M, Mattmann C, Tschopp J (1994) Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 370:650
71. Lustgarten J, Eshhar Z (1995) Specific elimination of IgE production using T cell lines expressing chimeric T cell receptor genes. Eur J Immunol 25:2985
72. Lynch DH, Watson ML, Alderson MR, Baum PR, Miller RE, Tough T, Gibson M, Davis Smith T, Smith CA, Hunter K (1994) The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity 1:131
73. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G (1991) By-passing immunization: human antibodies from V-gene libraries displayed on phage. J Mol Biol 222:581
74. McCafferty J, Griffiths AD, Winter G, Chiswell DJ (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348:552
75. Mezzanzanica D, Garrido MA, Neblock DS, Daddona PE, Andrew SM, Zurawski VR Jr, Segal DM, Wunderlich JR (1991) Human T-lymphocytes targeted against an established ovarian carcinoma with bispecific F(ab')2 antibody prolong host survival in a murine xenograft model. Cancer Res 51:5716
76. Moretta A, Poggi A, Pende D, Tripodi G, Orengo AM, Pella N, Augugliaro R, Bottino C, Ciccone E, Moretta L (1991) CD69-mediated pathway of lymphocyte activation: anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressing T cell receptor α/β. J Exp Med 174:1393
77. Moritz D, Wels W, Mattern J, Groner B (1994) Cytotoxic T lymphocytes with grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci USA 91:4318
78. Nishioka WK, Welsh RM (1994) Susceptibility to cytotoxic T-lymphocyte-induced apoptosis of the proliferative status of the target. J Exp Med 179:769
79. Pack P, Pluckthun A (1992) Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli. Biochemistry 31:1579
80. Perez P, Hoffmann RW, Shaw S, Bluestone JA, Segal DM (1985) Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 316:354
81. Philips JH, Gumperz JE, Parham P, Lanier LL (1995) Superantigen-dependent, cell-mediated cytotoxicity inhibited by MHC class I receptors on T lymphocytes. Science 268:403
82. Podack ER, Hengartner H, Lichtenheld MG (1991) A central role of perforin in lymphocyte-mediated cytotoxicity. Annu Rev Immunol 9:129
83. Qian J-H, Titus JA, Andrew SM, Mezzanzanica D, Garrido MA, Wunderlich JR, Segal DM (1991) Human PBL targeted with bispecific antibodies release cytokines that are essential for inhibiting tumor growth. J Immunol 146:3250
84. Ridge JP, Fuchs EJ, Matzinger P (1996) Neonatal tolerance revisited: turning on newborn T cells with dendritic cells. Science 271:1723
85. Roberts MR, Qin L, Zhang D, Smith DH, Tran A-C, Dull TJ, Groopman JE, Capon DJ, Byrn RA, Finer MH (1994) Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood 84:2878
86. Romani L, Mocci S, Bietta C, Lanfaloni L, Puccetti P, Bistoni F (1991) Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance. Infect Immun 59:4647
87. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE (1988) Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319:1676
88. Rosenberg SA, Yanelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86:1159
89. Russell JH (1983) Internal disintegration model of cytotoxic lymphocyte-induced target damage. Immunol Rev 72:97
90. Saizawa K, Rojo J, Janeway JA Jr (1987) Evidence for a physical association of CD4 and the CD3: α:β T-cell receptor. Nature 328:260
91. Salmeron A, Sanchez-Madrid F, Ursa MA, Fresno M, Alarcon B (1991) A conformational epitope expressed upon association of CD3-epsilon with either CD3-delta or CD3-gamma is the main target for recognition by anti-CD3 monoclonal antibodies. J Immunol 147:3047
92. Schwartz RH (1992) Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71:1065
93. Sconocchia G, Titus JA, Segal DM (1994) CD44 is a cytotoxic triggering molecule in human peripheral blood NK cells. J Immunol 153:5473
94. Segal DM, Snider DP (1989) Targeting and activation of cytotoxic T lymphocytes. Chem Immunol 47:179
95. Segal DM, Urch CE, George AJT, Jost CR (1992) Bispecific antibodies in cancer treatment. In: DeVita VT, Hellman S, Rosenberg SA (eds) Biologic therapy of cancer updates, vol. 2. Lippincott, Philadelphia, pp 1-12
96. Segal DM, Jost CR, George AJT (1993) Targeted cellular cytotoxicity. In: Sitkovsky MV, Henkart PA (eds) Cytotoxic cells: generation, recognition, effector functions, methods. Springer, New York, Berlin Heidelberg pp 96-110
97. MEL-14. Proc Natl Acad Sci USA 88:7877
98. Shalaby MR, Shepard HM, Presta L, Rodrigues ML, Beverley ACL, Feldmann M, Carter P (1992) Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. J Exp Med 175:217
99. Shinkai Y, Takio K, Okumura K (1988) Homology of perforin to the ninth component of complement (C9). Nature 334:525
100. Shiver JW, Henkart PA (1991) A noncytotoxic mast cell tumor line exhibits potent IgE-dependent cytotoxicity after transfection with the cytolysin/perforin gene. Cell 64:1175
101. Shiver JW, Su L, Henkart PA (1992) Cytotoxicity with target DNA breakdown by rat basophilic leukemia cells expressing both cytolysin and granzyme A. Cell 71:315
102. Springer TA (1990) Adhesion receptors of the immune system. Nature 346:425
103. Stancovski I, Schindler DG, Waks T, Yarden Y, Sela M, Eshhar Z (1993) Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J Immunol 151:6577
104. Street NE, Mosmann TR (1991) Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J 5:171
105. Tibben JG, Boerman OC, Claessens RAMJ, Corstens FHM, Van Deuren M, De Mulder PHM, Van der Meer JWM, Keijser KGG, Massuger LFAG (1993) Cytokine release in an ovarian cancer patient following intravenous administration of bispecfic antibody OC/TR F(ab')2. J Natl Cancer Inst 85:1003
106. Titus JA, Garrido MA, Hecht TT, Winkler DF, Wunderlich JR, Segal DM (1987) Human T cells targeted with anti-T3 crosslinked to anti-tumor antibody prevent tumor growth in nude mice. J Immunol 138:4018
107. Trauth BC, Klas C, Peters AM, Matzku S, Möller P, Falk W, Debaten K-M, Krammer PH (1989) Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245:301
108. Tschopp J, Nabholz M (1990) Perforin-mediated target cell lysis by cytolytic T lymphocytes. Annu Rev Immunol 8:279
109. Valitutti S, Müller S, Cella M, Padovan E, Lanzavecchia A (1995) Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 375:148
110. - clones, regulated via CD3 and CD16 activation sites, recombinant interleukin 2 and Interferon β. J Immunol 138:1627
111. + killer cell cones by monoclonal antibodies (anti-CD16, anti-CD2, anti-CD3) depends on subclass specificity of target cell IgG-FcR. J Immunol 138:3137
112. Van Ravenswaay Claasen HH, Van de Griend RJ, Mezzanzanica D, Bolhuis RLH, Warnaar SO, Fleuren GJ (1993) Analysis of production, purification, and cytolytic potential of bispecific antibodies reactive with ovarian-carcinoma-associated antigens and the T cell antigen CD3. Int J Cancer 55:128
113. Van Ravenswaay Claasen HH, Eggermont AM, Nooyen YA, Warnaar SO, Fleuren GJ (1994) Immunotherapy in a human ovarian cancer xenograft model with two bispecific monoclonal antibodies: OV-TL3/CD3 and OC/TR. Gynecol Oncol 52:199
114. Van Seventer GA, Shimizu Y, Shaw S (1991) Roles of multiple accessory molecules in T-cell activation. Curr Opin Immunol 3:294
115. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, McCafferty J, Hodits RA, Wilton J, Johnson KS (1996) Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nature Biotechnol 14:309
116. Walsh CM, Glass AA, Chiu V, Clark WR (1994) The role of the Fas lytic pathway in a perforin-less CTL hybridoma. J Immunol 153:2506
117. Weiner GJ, Hilstrom JR (1991) Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma. J Immunol 147:4035
118. Weiner GJ (1992) Bispecific IgG and IL-2 therapy of a syngeneic B-cell lymphoma in immunocompetent mice. Int J Cancer [Suppl] 7:63
119. Weiner GJ, Kostelny SA, Hillstrom JR, Cole MS, Link BK, Wang SL, Tso JY (1994) The role of T cell activation in anti-CD3 × antitumor bispecific antibody therapy. J Immunol 152:2385
120. Weis W, Harwerth IM, Hynes NE, Groner B (1992) Diminution of antibodies directed against tumor cell surface epitopes: a single chain Fv fusion molecule specifically recognizes the extracellular domain of the c-erb B2 receptor. J Steroid Biochem Mol Biol 43:1
121. Winter G, Milstein C (1991) Man-made antibodies. Nature 349:293
122. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR (1994) Making antibodies by phage display technology. Annu Rev Immunol 12:433
123. Zhu Z, Zapata G, Shalaby R, Snedecor B, Chen H, Carter P (1996) High level secretion of a humanized bispecific diabody from Escherichia coli. Biotechnology 14:192